Status:
COMPLETED
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer
Lead Sponsor:
Instituto do Cancer do Estado de São Paulo
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Thyroid Cancer, Papillary
Primary Aldosteronism
Eligibility:
All Genders
18+ years
Brief Summary
Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies. A hi...
Detailed Description
Primary aldosteronism (PA) is the most frequent cause of endocrine hypertension, with an estimated prevalence of 20% among individuals with resistant hypertension. PA is associated with an increased r...
Eligibility Criteria
Inclusion
- All patients with PTC and EH regardless of hypertension severity
Exclusion
- Patients who were using medications that secondarily increase blood pressure levels were excluded
- Did not agree to participate
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
274 Patients enrolled
Trial Details
Trial ID
NCT06068101
Start Date
March 1 2019
End Date
August 1 2023
Last Update
October 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ana Alice Wolf Maciel
São Paulo, Brazil, 01246-000